Roth Mkm Issues Pessimistic Forecast for OptimizeRx (NASDAQ:OPRX) Stock Price

OptimizeRx (NASDAQ:OPRX) had its target price dropped by Roth Mkm from $32.00 to $18.00 in a research report issued on Friday,Benzinga reports. The firm presently has a “buy” rating on the stock. Roth Mkm’s price target suggests a potential upside of 167.06% from the company’s previous close.

Several other equities analysts have also recently weighed in on the company. Stephens decreased their price objective on OptimizeRx from $17.00 to $10.00 and set an “equal weight” rating for the company in a report on Friday. Wall Street Zen upgraded OptimizeRx from a “buy” rating to a “strong-buy” rating in a report on Sunday, December 14th. Stifel Nicolaus reduced their price target on OptimizeRx from $21.00 to $17.00 and set a “buy” rating for the company in a research report on Friday. Weiss Ratings restated a “sell (d+)” rating on shares of OptimizeRx in a research note on Monday, December 22nd. Finally, Citizens Jmp boosted their price target on OptimizeRx from $23.00 to $24.00 and gave the stock a “market outperform” rating in a research report on Friday, November 7th. Six investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $17.57.

OptimizeRx Stock Performance

Shares of OPRX opened at $6.74 on Friday. OptimizeRx has a 12 month low of $3.99 and a 12 month high of $22.25. The firm has a fifty day simple moving average of $10.52 and a 200 day simple moving average of $14.72. The stock has a market capitalization of $125.63 million, a price-to-earnings ratio of 25.92 and a beta of 1.20. The company has a current ratio of 3.05, a quick ratio of 3.05 and a debt-to-equity ratio of 0.20.

OptimizeRx (NASDAQ:OPRX) last issued its quarterly earnings results on Saturday, January 31st. The company reported $0.51 earnings per share (EPS) for the quarter. OptimizeRx had a net margin of 4.69% and a return on equity of 10.81%. Research analysts forecast that OptimizeRx will post -0.33 EPS for the current fiscal year.

OptimizeRx declared that its board has approved a stock repurchase plan on Thursday, March 5th that permits the company to repurchase $10.00 million in outstanding shares. This repurchase authorization permits the company to buy up to 6.8% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company’s management believes its shares are undervalued.

Institutional Trading of OptimizeRx

Several hedge funds have recently added to or reduced their stakes in OPRX. Nisa Investment Advisors LLC boosted its stake in OptimizeRx by 600.0% in the 2nd quarter. Nisa Investment Advisors LLC now owns 2,121 shares of the company’s stock valued at $29,000 after purchasing an additional 1,818 shares during the period. Quantbot Technologies LP acquired a new position in OptimizeRx in the 2nd quarter valued at $44,000. BNP Paribas Financial Markets increased its position in OptimizeRx by 119.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 4,074 shares of the company’s stock worth $55,000 after buying an additional 2,215 shares during the period. State of Alaska Department of Revenue bought a new position in OptimizeRx during the 4th quarter worth $62,000. Finally, USA Financial Formulas acquired a new stake in shares of OptimizeRx during the third quarter worth $131,000. 76.47% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting OptimizeRx

Here are the key news stories impacting OptimizeRx this week:

• Positive Sentiment: Q4 earnings and revenue beat expectations — OPRX reported stronger-than-expected results (EPS and revenue topped consensus), supporting the company’s underlying growth narrative. Q4 Results
• Positive Sentiment: Board authorized a $10.0M share repurchase program (up to ~6.8% of shares), a shareholder-friendly move that typically supports share price over time by reducing float. Buyback Announcement
• Neutral Sentiment: Roth MKM lowered its price target from $32 to $18 but kept a “buy” rating — still a materially higher target than current levels, creating mixed signals (cut in optimism but continued buy conviction). Roth MKM PT Change
• Neutral Sentiment: Multiple brief trading halts for OPRX were reported today due to LULD pauses — technical market safeguards that can amplify volatility but do not convey fundamental news.
• Negative Sentiment: FY2026 revenue guidance came in at $109M–$114M versus consensus near $122M — a notable shortfall that likely drove investor disappointment and downward pressure on the stock. Guidance Story
• Negative Sentiment: B. Riley reaffirmed its buy rating but cut its price target from $28 to $11 — another analyst reduction that removes prior upside and likely contributed to selling pressure. B. Riley PT Cut
• Negative Sentiment: Stephens trimmed its target to $10 and set an “equal weight” rating, signaling a more cautious view and reducing analyst-driven upside expectations. Stephens PT Change

OptimizeRx Company Profile

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.